The OncoAlert🚨ROUND UP
Covering May 2-8, 2024

👇👇👇

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Comprehensive mutational scanning of #EGFR reveals TKI sensitivities of extracellular domain mutants. shorturl.at/lrI45

🧬Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, were sensitive to afatinib and dacomitinib in vitro.…

The 🚨 OncoAlert newsletter is out!! Covering May 2-8, 2024. #OncoAlertAF
👇
REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……

The Lancet Commission highlights the urgent need to address the projected doubling of global #ProstateCancer cases by 2040

Doing so by:
✅Early diagnosis strategies
✅Equitable access to care
✅increased research focus on ethnic disparities and treatment distribution in LMICs…

DESTINY-PanTumor01 :Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

#LungCancer 🫁
OncoAlert 🚨

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.

DESTINY-PanTumor01
Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

✅Demonstrating significant anti-tumor activity and durable responses, alongside manageable safety profiles

➡️suggesting potential…

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &…

Important effort to out in Nature Communications characterizing FAK-YAP signaling as mediator of residual disease during targeted therapies in #NSCLC .

✅FAK-YAP inhibition + targeted therapy 💊 combo suppresses residual drug-tolerant cells.
🚨🚨OncoAlert #LCSM
shorturl.at/aexAO

The new OncoAlert 🚨 newsletter is OUT!
Don’t miss it! And if you don’t have a subscription, register at oncoalert.m-pages.com/nhMpwe/oncoale… for the latest in oncology.

Just out on Journal for ImmunoTherapy of Cancer 🚨
The Society for Immunotherapy🧪 of Cancer's expert panel devised tailored clinical trial designs to maximize the efficacy of intratumoral immunotherapies across various stages of #Cancer

✅addressing key considerations such as patient selection,…

Gefitinib + chemotherapy combo continues to show ⬆️PFS & OS at 5y of follow-up vs gefitinib monotherapy in #EGFR + #NSCLC .
5-year OS: 13% vs 4.4% (HR, 0.58). 5-year PFS: 6.7% vs 1.7% (HR, 0.53). Implications for countries with limited access to 3rd gen TKIs 🚨🚨OncoAlert #LCSM

Dear Colleagues,
One Month until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽…

If you are attending #ASCO24 don’t forget to register to the 🚨 OncoAlert 5K walk/run. June 1st, 7 AM. Start Hyatt Regency at McCormick Place, Chicago!
⬇️⬇️⬇️

Dear Colleagues
Grab your morning coffee☕️Get comfortable and get ready to have some FUN with GU Cast | Urology podcast! , Uromigos and OncoAlert 🚨as we have some amazing conversation right next to Lake Lugano at #APCCC24 🇨🇭

We Love this Lot and dont forget to follow:
Declan Murphy🇦🇺…

AN AMAZING TWEETORIAL
SUM Up of FIRST DAY OF #APCCC24 🇨🇭
Author: #OncoAlertAF Dra. María Natalia Gandur Quiroga 🇦🇷

Pinging OncoAlert 🚨GU faculty
Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas Tian Zhang, MD, MHS Hans Hammers Ravindran Kanesvaran Neeraj Agarwal, MD, FASCO Axel S. Merseburger…

Somethings a Brewin here in Lugano🇨🇭
Live from #APCCC24
Uromigos GU Cast | Urology podcast! OncoAlert 🚨
WEBCAST...Coming Soon‼️

Declan Murphy 🇦🇺
Renu Eapen 🇦🇺
Brian Rini, MD 🇺🇸
Tom Powles 🇬🇧
Gil Morgan, MD 🇺🇸

Sumanta K. Pal, MD, FASCO Cristiane D Bergerot Daniel Heng Andrea Apolo, M.D. Toni Choueiri, MD Petros Grivas…

In a new study published in JTO & JTO CRR IASLC, Biagio Ricciuti, MD PhD and @danafarber researchers showed improved long-term survival with pembrolizumab & cemiplimab in NSCLC patients with PD-L1 >90% vs 50-89%. #LCSM
Read more here: ms.spr.ly/6010YyynQ

Check out the new OncoAlert newsletter (April 19-24, 2024). Thank you Gil Morgan, MD for keeping the community updated!!